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Abstract
Background: Reports of increased morbidity and mortality from infectious diseases among HIV Exposed Uninfected
(HEU) infants have raised concern about a possible underlying immunodeficiency among them. The objective of
this study was to assess the immunological profile of HEU infants born to mothers exhibiting different levels of
HIV-1 viremia at the time of delivery.
Methods: Study subjects were enrolled in the Centre maternel et infantile sur le SIDA (CMIS) mother-child cohort
between 1997 and 2010 (n =585). Infant CD4+ T cell, CD8+ T cell and CD19+ B cell counts were assessed at 2 and
6 months of age, and compared among HEU infants in groups defined by maternal viral load (VL) at the time of
delivery (VL < 50 copies/ml, VL 50–1000 copies/ml, and VL > 1000 copies/ml) in a multivariable analysis.
Results: At 2 months of age, infants born to mothers with VL > 1000 copies/ml had lower CD4+ T cell counts
compared to those born to mothers with VL < 50 copies/ml at the time of delivery (44.3% versus 48.3%, p = 0.007,
and 2884 vs. 2432 cells/mm3, p = 0.02). These differences remained significant after adjusting for maternal and
infant antiretroviral drug use, gender, race and gestational age, and persisted at 6 months of age. There were no
differences in CD8+ T cell count or absolute CD19+ B cell count between groups, though higher CD19+ B cell
percentage was seen among infants born to mothers with VL > 1000 copies/ml.
Conclusions: These results suggest that exposure to high levels of HIV-1 viremia in utero, even in the absence of
perinatal transmission, may affect the infant’s developing immune system. While further work needs to be done to
confirm these findings, they reinforce the need for optimal treatment of HIV infected pregnant women, and careful
follow-up of HEU infants.
Keywords: Mother-to-child HIV human immunodeficiency virus transmission, Antiretroviral drugs, Viral load,
Immune suppression, Immune system
Background
The development and successful implementation of
prevention of mother-to-child transmission (PMTCT)
programs has reduced the risk of perinatal transmission of
HIV-1 from 25-30% to less than 1% [1,2]. In Canada, as in
many parts of the developed world, HIV-exposed unin-
fected (HEU) infants significantly outnumber those who
are infected [3]. However, despite successfully averting
HIV-1 infection, there is emerging concern about the
health of HEU infants [4]. Reports from South Africa, the
Caribbean, South-East Asia and Europe have found
increased morbidity and mortality from infectious diseases
among HEU infants [5-9]. HEU infants have been found to
have a higher incidence of neonatal infections, neonatal
sepsis, respiratory illness, acute gastroenteritis, hospitaliza-
tion, and post-operative complications compared to the
general population [10-15], and compared to HIV-
unexposed uninfected controls [16,17]. Perhaps most con-
cerning are reports of pneumonia caused by Pneumocystis
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jiroveci, normally considered to be an HIV-associated
opportunistic infection, among HEU infants [18-20].
While the cause of this increased morbidity and mortal-
ity from infectious diseases among HEU infants is likely to
be multifactorial, encompassing environmental, maternal,
and health systems factors, the increased burden of infec-
tions seen among them raises the question of whether a
relative state of immunodeficiency may contribute to their
increased susceptibility to disease [21]. A number of stud-
ies to date have shown evidence of various immunological
abnormalities among HEU children. The most consistent
findings have been markers of increased immune activa-
tion and reduced total and naive CD4+ T cell counts in
HEU newborns [22-26]. It is hypothesized that these
immunological changes may result from a combination of
factors whereby the in utero environment of HIV infected
mothers uniquely shapes their infant’s immune system.
Previous studies have shown an association between
maternal antiretroviral (ART) drug use and lower infant
CD4 counts and thymic CD4 output [27,28], maternal
CD4 count and infant CD4 count [29,30], and maternal
recreational drug use and lower infant CD4 counts [31],
though few have studied the impact of maternal HIV-1
viremia on infant immunological parameters. However,
there is increasing evidence across a range of infectious
diseases (viral, bacterial and parasitic) to suggest that
chronic maternal infections during pregnancy can affect
an infant’s immune response to future infections, inde-
pendently of the vertical transmission of pathogens [32]. In
utero sensitization of the fetal immune system to maternal
pathogens is thought to lead to altered cytokine, prolifera-
tive, and antibody responses to these pathogens in the infant
[33-35]. There is evidence that HEU infants are exposed to
HIV-1 in utero; circulating HIV-1 proteins and/or immune
complexes have been shown to induce strong HIV-specific
T helper and cytotoxic T cell responses in HEU newborns,
when these infants clearly are uninfected [36-39].
Given the reports of increased morbidity and mortality
from infectious diseases among HEU infants, and our
limited understanding on the nature and cause of
immune abnormalities in these children, the objective of
the present study was to test the hypothesis that is in
utero exposure to high levels of HIV-1 viremia may drive
the immunological changes seen among HEU, in the
absence of acute infection.
Methods
Study population
The Centre maternel et infantile sur le SIDA (CMIS)
Mother-Child Cohort was established in 1988 to pro-
spectively follow all pregnant HIV-infected women and
their newborns presenting to Centre hospitalier universi-
taire (CHU) Sainte-Justine, a tertiary referral center in
Montreal, Canada. HIV infected women were treated by
a mutlidisplinary obstetrics-infectious diseases team on
site, and HIV-1 plasma RNA levels at the time of deliv-
ery were measured in real time using the Versant HIV-1
RNA assay (Bayer, Pittsburg), with a detection threshold
of 2.70 log10 (500) HIV-1 RNA copies/ml (version 2.0,
1997–2000), or 1.70 log10 (50) HIV RNA copies/ml
plasma (version 3.0, 2000–2010).
HIV exposed infants were followed closely in the first
2 years of life to determine their HIV status and to moni-
tor for the effects of in utero and post-natal exposure to
ART. HIV infection status in infants was determined
using 4 negative HIV-1 DNA PCR tests (2 weeks, 1 month,
2 month and 4 months of life) (Roche Amplicor), and the
absence of HIV-1 antibodies by ELISA at or after
18 months of age. All infants in the cohort were exclu-
sively formula fed, and received 6 weeks of ART for
prevention of mother-to-child transmission as soon as it
became available. This resulted in different neonatal treat-
ment regimens over time. From 1994–1997, infants at our
center received AZT alone, from 1998–1999 AZT in com-
bination with 3TC, and from 1999–2007, AZT, 3TC and
Nelfinavir. Following the recall of Nelfinavir in 2007, the
neonatal regimen changed again from 2007–2010 to a
combination of AZT and 3TC. Clinical and laboratory
monitoring included complete physical exam at every
visit, routine haematology and biochemistry tests until
18 months of age, and numeration of lymphocyte subsets
(CD4+ T cells, CD8+ T cells, CD19+ B cells) by flow
cytometry at 2 and 6 months of age. After 2 years of age,
children were offered annual pediatric follow up until age
5, and every 2 years thereafter. Demographic and labora-
tory data were collected at every visit and entered into the
CMIS database. Informed consent was sought and
obtained from all participants to the CMIS Cohort. This
protocol was reviewed and approved by the Ethics Review
Board of CHU Sainte-Justine, Montreal, Canada, where
the study was conducted.
All HEU infants born between 1997 and 2010 were
eligible for the study, though infants for whom immuno-
logical data was not available at the specified ages of 2 and
6 months (due to visits outside of the routine schedule)
were excluded from the analysis, given the large variability
in infant lymphocyte subsets over the first few months of
life. Out of a total 585 mother-infant pairs, 424 mother-
infant pairs were assessed at 2 months of age and 380 at
6 months of age (Figure 1).
Statistical analysis
Descriptive statistics were used to characterize the study
population. For continuous variables, means and ranges
were reported. For discrete variables, percentages were
reported. For the primary analysis, infants were then
categorized into 3 groups based on maternal VL closest
to delivery, i.e. > 1,000, 50–1,000, and < 50 HIV-1 RNA
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copies/ml plasma. Given the changes in the sensitivity of
VL testing over time, infants born to mothers with VL
<500 HIV-1 RNA copies/ml plasma (n = 12), while con-
sidered undetectable at the time, were removed from the
analysis given that we could not be certain about their
true VL, and in order to ensure heterogeneity within
strata. Infant CD4+ T cell, CD8+ T cell, and CD19+ B cell
counts (relative and absolute) were then compared
among infants in each of these 3 maternal VL strata using
one-way analysis of variance. Multivariable analysis of
variance was conducted to adjust for confounders identi-
fied a priori from published literature [22-26], including
maternal CD4+ T cell counts, exposure to ART (mother
and infant), gestational age, gender and race. The different
models used in the final analysis and the significance of
each variable included are presented as supplementary
information in an Additional file 1: Table S1. All statistical
tests were 2-sided and statistical significance threshold
was set at p < 0.05. All data were analyzed using SAS
version 9.2 (SAS Institute, Cary, NC).
Results
Maternal characteristics
Among HIV-infected mothers, 12.3% received no ART,
13.2% were treated with zidovudine (AZT) monotherapy,
8.4% with double combination therapy (AZT and lamivu-
dine [3TC]), and 66.2% received combination ART (cART)
during pregnancy. Median maternal age was 31 years (IQ =
27–34 years). 71.9% of mothers were categorized as not im-
munosuppressed at delivery (CD4 > 350 cells/mm3), while
19.7% were moderately immunosuppressed (CD4 = 200–
350 cells/mm3) and 8.4% were severely immunosuppressed
(CD4 < 200 cells/mm3). HIV-1 VL at delivery was undetect-
able (<50 HIV-1 RNA copies/ml plasma) in 77.7% of
mothers, 11.7% had a VL between 50 and 1,000 HIV-1
copies/ml plasma, and 10.4% had VL > 1,000 HIV-1 RNA
copies/ml plasma. Among those with VL >1000 copies/ml,
median VL was 6352 (IQR 2600–10433 copies/ml). Mater-
nal characteristics according to delivery viral load are sum-
marized in Table 1.
Infant characteristics
46.7% of infants were female and 53.3% were male. 29.7%
were identified as Caucasian, 63.2% were black, 4.6% were
mixed, and 2.5% were classified as other. When grouped by
region of origin, 33.1% of infants were classified as African,
31.5% were Haitian, 28.4% Canadian, and the remaining
7.0% mixed-Canadian or other. With respect to ART given
to newborns for PMTCT, 12.9% received no ART, 11.5%
received AZT monotherapy, 28.7% received AZT and 3TC,
and 46.9% received 3 or more antiretroviral agents.
Lymphocyte subsets
Infant CD4+ T cell counts
There was a significant difference in CD4+ T cell counts
at both 2 and 6 months of age among infants born to
mothers with HIV-1 VL > 1,000 vs. < 50 HIV-1 RNA
copies/ml plasma (Tables 2 and 3). At 2 months of age,
infants born to mothers with undetectable VL had
higher CD4 counts compared to those with VL > 1,000
HIV-1 RNA copies/ml plasma (48.3% vs. 44.3%, p =
0.007 and 2884 vs. 2432 cells/mm3, p = 0.02). These
Figure 1 Participant enrollment and flow diagram for mother-infant pairs included in the analysis at 2 and 6 months of age.
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differences persisted at 6 months of age (46.1% vs. 42.1%,
p = 0.009, and 2887 vs. 2271 cells/mm3, p = 0.002), and
remained statistically significant after adjusting for gesta-
tional age, race, gender, maternal and infant ART exposure,
and maternal CD4+ T cell counts at the time of delivery.
Infant CD19+ B cell counts
There was a significant difference in the percentage of
CD19+ B cells among infants born to mothers with HIV-
1 VL > 1,000 vs. < 50 RNA copies/ml plasma at 2 and
6 months of age, with higher CD19+ B cell percentages
among infants born to mothers with higher VL (>1,000
copies) compared to those whose mothers were un-
detectable at the time of delivery (28.7% vs. 24.5%, p =
0.003, and 30.8% vs. 26.6%, p =0.008, respectively).
This difference remained significant after adjusting for
gestational age, race, gender, maternal and infant ART ex-
posure, and maternal CD4+ T cell counts at the time of
delivery (p = 0.01 and p < 0.001, respectively). The differ-
ences in absolute CD19 count at 2 and 6 months of age
(1479 vs. 1446 cells/mm3 and 1528 vs. 1687 cells/mm3)
were not statistically significant (p = 0.79 and p = 0.27, re-
spectively), both in the unadjusted and adjusted analysis.
Infant CD8+ T cell counts
There was no significant difference in CD8+ T cell count
(absolute or percentage) among infants born to mothers
with HIV-1 VL > 1000 vs. < 50 RNA copies/ml plasma at
2 months of age (15.5% vs. 15.4%, p = 0.90 and 849 vs. 931,
p = 0.26) nor at 6 months of age (15.2 vs. 15.2, p = 0.99
and 828 vs 961 cells/mm3, p = 0.10), both unadjusted and
adjusted.
Discussion
This study of HEU infants in Canada revealed differences
in infant CD4+ T cell counts as a function of maternal
HIV-1 VL measured at the time of delivery. Decreased
CD4+ T counts (relative and absolute) were observed at 2
and 6 months of age in infants born to mothers with a
VL > 1000 copies/ml at the time of delivery, when com-
pared to infants born to mothers with undetectable viral
load (<50 copies/ml). Our findings are consistent with a
recent study from Malawi [40] which also found decreased
CD4% at one month of age among HEU infants compared
to unexposed uninfected controls, with CD4 values (mean
44% IQR 39–50) similar to those reported in the present
study among 2 month old infants born to mothers with
VL > 1000 copies/ml (mean 44.4, 95% CI 41.3-47.5).
Though the specific mechanisms behind this association
have yet to be understood, it has been shown that HIV-
infected, ART-treated women have greatly increased pla-
cental production of inflammatory cytokines, tumor
necrosis factor alpha (TNF-α), and interleukin 8 (IL-8)
compared to uninfected women [41,42], and mothers with
high VL have been shown to generate higher levels of the
pro-inflammatory cytokines INF-δ and TNF-α [43]. This
pro-inflammatory, immune activated intra-uterine state is
likely be increased in women with poorly controlled HIV-
1 viremia, and could potentially be the driving force be-
hind the differences in CD4 count seen in this study
among the infants born to mothers defined by extremes of
maternal viral control (<50 vs. >1000 copies/ml).
The significance of the changes in CD19+ B cell
counts is not clear. Infants born to mothers with VL >
1000 copies/ml at the time of delivery had an increased
Table 1 Maternal characteristics according to delivery viral load
Maternal group Viral load <50 copies/ml Viral load 50–1000 copies/ml Viral load >1000 copies/ml
Median viral load (IQR) NA 244 (105–506) 6 252 (2600 – 10433)
Maternal age
(Mean, SD) 31.5 (5.5) 29.8 (5.3) 30.8 (5.2)
Delivery CD4 count (n, %)
>350 276 (80.5) 34 (63.0) 27 (58.7)
200-350 49 (14.3) 9 (16.7) 8 (17.4)
<200 18 (2.2) 11 (20.4) 11 (23.9)
Gestational age
(Mean, SD) 38.5 (2.2) 38.1 (1.9) 37.7 (2.7)
Pre-term (n, %)
(<37 weeks) 50 (14.1) 9 (16.4) 9 (18.8)
ART regimen
None 3 (0.9) 2 (3.7) 6 (12.5)
AZT 5 (1.4) 3 (5.6) 7 (14.6)
AZT/3TC 27 (7.6) 6 (11.1) 4 (8.3)
cART 319 (90.1) 43 (79.6) 21 (64.6)
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Table 2 Infant CD4, CD19 and CD8 parameters at 2 months of age













>1000 Relative* 44.3 (41.5–47.0) 0.007 43.5 (40.6–46.3) 0.001 28.7 (26.1–31.4) 0.003 29.3 (26.4–32.2) 0.001 15.5 (14.0–17.1) 0.90 16.0 (14.4–17.6) 0.58
Absolute** 2432 (2072–2792) 0.02 2395 (2009–2781) 0.022 1479 (1255–1703) 0.79 1510 (1272–1747) 0.49 849 (713–985) 0.26 868 (721–1015) 0.94
50–1000 Relative 48.7 (46.2–51.3) 0.74 48.6 (46.1–51.0) 0.99 23.8 (21.3–26.4) 0.65 24.2 (21.7–26.7) 0.96 15.8 (14.4–17.2) 0.68 15.6 (14.2–17.0) 0.73
Absolute 2872 (2533–3210) 0.94 2888 (2548–3229) 0.96 1375 (1165–1585) 0.53 1416 (1206–1625) 0.57 952 (824–1079) 0.77 947 (817–1077) 0.80








15.4 (14.9–16.0) Ref 15.5 (15.0–16.1)
Ref
Absolute 2884 (2759–3010) 2878 (2751–3005) 1446 (1369–1523) 1419 (1342–1497) 931 (884–979) 930 (882–979)
*Relative counts are reported as percentages.
**Absolute counts are reported as cells/mm3.
†Comparing means in group VL > 1000 and VL 50–1000 to VL < 50 (reference group) using sum of least squares.



















Table 3 Infant CD4, CD19 and CD8 parameters at 6 months of age













>1000 Relative* 42.1 (39.3–44.9) 0.009 40.1 (37.1–43.1) <0.001 30.8 (27.9–33.7) 0.008 32.9 (29.8–36.1) <0.001 15.2 (13.6–16.8) 0.99 14.9 (13.2–16.6) 0.73
Absolute** 2271 (1907–2635) 0.002 2290 (1893–2687) 0.022 1528 (1261–1794) 0.27 1712 (1420–2003) 0.73 828 (680–977 0.10 853 (690–1016) 0.95
50-1000 Relative 47.0 (44.5–49.4) 0.52 46.8 (44.3–49.2) 0.78 27.0 (24.5–29.6) 0.75 27.8 (25.2–30.4) 0.27 15.8 (14.4–17.1) 0.43 15.3 (13.9–16.7) 0.24
Absolute 2861 (2540–3181) 0.88 2876 (2550–3202) 0.96 1727 (1492–1961) 0.76 1788 (1549–2027) 0.32 937 (806–1068) 0.74 926 (792–1060) 0.68












Absolute 2887 (2756–3017) 2878 (2747–3010) 1687 (1592–1783) 1656 (1559–1752) 961 (908–1014) 957 (903–1011)
*Relative counts are reported as percentages.
**Absolute counts are reported as cells/mm3.
†Comparing means in group VL > 1000 and VL 50–1000 to VL < 50 (reference group) using sum of least squares.



















CD19+ B cell percentage, though no change was seen in
their absolute CD19+ B cell count. To date, B cell func-
tion among HEU infants is not well understood. Some
studies have shown a more robust antibody response to
vaccines among HEU infants as compared to unexposed,
uninfected controls [44,45]. When compared to Hepa-
titis C exposed infants, HEU infants have been shown to
have lower levels of transferred maternal antibodies at
birth and significantly higher total immunoglobulin
levels until 2 years of age [46], and it is thought that
reduced maternal antibody interference with vaccines
may contribute to a stronger vaccine response. However,
others studies have reported decreased neutralizing-
antibody titres to the oral poliovirus vaccine [47] and
diminished response to the Hepatitis B vaccine among
HEU infants [48]. Given the uncertainty surrounding B
cell function among HEU, it is not clear if our findings
of decreased CD19% in the absence of changes to abso-
lute CD19 count are suggestive of an altered overall
immunological profile in response to aggravated HIV
exposure, or simply represent an isolated finding.
Our study is limited by our ability to control for other
confounders that are both known and hypothesized to
affect infant immune status, including malnutrition,
recreational exposure to hard drugs, and cytomegalovirus
co-infection status [21]. While all women in our cohort
received identical treatment by the same team of care-
givers under a system of universal healthcare access (in-
cluding social welfare benefits), we were unable to adjust
for individual differences in overall health, nutritional,
socioeconomic and social status. Most importantly, the
clinical implications of these subtle differences in CD4+ T
cell counts among HEU infants are not clear. Extrapolating
from studies in endemic settings, they may translate into
an increased susceptibility to infectious diseases. HEU
infants born to severely immunocompromised mothers
(CD4 < 200 cells/mm3) in a South African cohort were
found to be at higher risk of developing early- and late-
onset sepsis than those born to mothers with CD4 > 350
cells/mm3 [49]. Data from the Ban trial in Malawi further
demonstrated that low total white blood cell counts at
birth are a significant predictor of serious morbidity and
mortality among HEU infants [50]. The small differences
in CD4 count seen in the present study may further be
compounded by functional immune abnormalities, some-
thing that was not specifically examined.
Conclusion
In conclusion, the results of this study may contribute
to an understanding of the immune system of HEU
infants, and provide insight into the causes of the
increased morbidity and mortality from infectious
diseases seen among HEU infants in HIV-endemic
settings. Mothers with higher levels of HIV-1 viremia
are likely to be sicker, experience faster disease progres-
sion, and be less able to care for their infants. These
infants, though uninfected, possibly take 2 hits: a rela-
tive state of immunodeficiency marked by decreased
CD4+ T cell count and decreased placental transfer of
protective maternal antibodies, and increased exposure
to infectious diseases from sicker parents. While in
well-resourced settings this may have little clinical impact
given access to treatment and care, in resource-limited
settings, susceptibility to even mild, self-limited diseases
such as upper respiratory tract infections or gastroenteritis
could lead to significant infant morbidity and mortality. In
short, these results reinforce the need for optimal treat-
ment of all HIV-infected pregnant women, both to pre-
vent perinatal HIV transmission, and to limit possible
adverse events resulting from in utero exposure to high
level HIV viremia. Further studies are needed to detail the
immunological response among these infants, and to
determine any functional immune abnormalities.
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